Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


F2G Ltd completes £6.3million financing round to fund preclinical and clinical development


PRESS RELEASE
18th August 2008

Manchester, UK, August 2008 - F2G Limited, the Manchester UK based antifungal drug discovery and development company, today announced the completion of a £6.3 million equity financing round with an international syndicate of investors.

The funding will be used, in part, to support the development of F2G’s novel antifungal lead compound which is currently in pre-clinical development. FG3622 is a potent, novel, small molecule antifungal, active against a wide range of clinically significant moulds. In addition it has a new Mechanism of Action for systemic antifungal agents.

F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. The antifungal market is currently estimated at over five and a half billion dollars annually and is growing steadily year on year. Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma.

The funding, led by BankInvest Biomedical Venture (Denmark), will allow F2G to accelerate the development of FG3622 and other novel antifungal agents. Merifin Capital, Astellas Venture Management and K Nominees also participated in the financing round.

Mr Shane Kelly, CEO of F2G Ltd, said: “This financing is a strong endorsement of the outstanding work performed by the F2G team. We are delighted with the continued support from our investors and the current funding represents complete validation of our lead program and other ongoing projects. The resources will allow the Company to push through the development of FG3622 and other interesting programs.”

Mr Jens Kindtler, Partner at BankInvest Biomedical Venture and Chairman of the F2G Board of Directors, commented: “We are delighted to continue our support of F2G.

FG3622 is an exciting, novel molecule that will impact heavily on the current antifungal market. There is significant clinical need for a new systemic agent and FG3622 has the potential to fulfil this gap.”

Contact:
Shane M. Kelly
Chief Executive Officer
Tel: (+44) 0161 785 1271
Fax: (+44) 0161 785 1273
Email: shanekelly@f2g.com
www.f2g.com


Publisher Contact Information:

F2G Ltd.
(+44) 0161 785 1271
shanekelly@f2g.com

Company profile of F2G Ltd.
Past press releases of F2G Ltd..

Data


27,026
Tech investments
From our Online Data Service
17,443
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
May 30€15.0MBiopharmaceuticals
May 28€15.0MDiagnostics
May 28€1.3MInternet services
May 25€1.0MOther Software
May 22N/AInternet services
May 20€4.3MArtificial Intelligence

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.